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locations was made. The inclusion criteria were patients 
diagnosed with HNSCC, completion of radiotherapy, 18F-FDG 
PET/CT based treatment planning and at least 6 months 
follow up time after completion of RT. The recurrence free 
frequency for this population was 77%.  
The patients went through RT with CTV volumes delineated 
for the lymph node regions and the primary tumor 
respectively and with the dosage of 70 Gy EQD2. 
The recurrence volumes were delineated on the treatment 
planning CT images by an experienced radiation oncologist 
guided by post treatment follow up data, post-PET-imaging 
and post-CT-imaging, but without use of the pretreatment 
PET images used in treatment planning.  
For the subpopulation with recurrences, the distribution of 
SUV in the recurrence volumes was analyzed patient by 
patient. CTV volumes without any recurrence were excluded. 
For each patient, a volume CTVcontrol was defined as the CTV 
volume excluding the recurrence volume, CTVrecurrence. Voxels 
with SUV lower than 1 were excluded and the remaining SUV 
were normalized through dividing by SUVmax. Probability Of 
Failure (POF) was defined as the SUV frequency in CTVrecurrence 
divided by the SUV frequency in the union of CTVrecurrence and 
CTVcontrol. The voxel specific TCP for 70 Gy EQD2 for each 
normalized SUV was defined as unity subtracted by the 
product of the recurrence frequency, 23%, with POF. 
Results: POF was found to approach unity when SUV goes to 
SUVmax, hence the correlation of location of recurrence with 
increasing SUV was strong. Figure 1 displays how these 
finding translates into a voxel specific TCP at the given dose 
70 Gy EQD2. 
 
 
Figure 1: Voxel specific TCP at 70 Gy EQD2 for each patient, 
represented as lines in different colors. 
The dashed line represents the voxel specific TCP at 70 Gy 
EQD2 merged for all patients.  
Conclusions: This study presents a feasible method for 
determining relationships between tumor control and image 
information in voxels based on retrospective data for patient 
groups demonstrating localized recurrences. The obtained 
results could form the basis for prescribing dose at a voxel 
level, i.e. for dose painting by numbers. 
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Purpose/Objective: Dose escalation to the gross tumour 
volume (GTV) has been proposed to improve local control in 
oesophageal cancer. However, a recent planning study for 
mid-oesophageal tumours [Warren IJROBP 2014] found that a 
simultaneous integrated boost (SIB) with acceptable heart 
and lung sparing was not possible for ~25% of patients when 
using arctherapy (RA). Intensity modulated proton therapy 
(IMPT) has been proposed to improve target coverage and 
normal tissue sparing compared to photon treatments [Welsh 
IJROBP 2011]. In this work optimal SIB RA and IMPT treatment 
plans and their robustness to set-up error and proton range 
error are compared.  
Materials and Methods: 21 mid-oesophageal cancer patients 
representative of planning target volume (PTV) size were 
selected from the SCOPE1 (ISRCTN 47718479) database (mean 
PTV = 334 cm3). These patients had mean PTV 327 cm3, range 
140-591 cm3. The protocol standard margins were re-applied 
to trial-derived GTV without modification to generate PTV1. 
A boost volume (PTV2) was created by adding an isotropic 0.5 
cm margin to the GTV. The dose prescription (25 fractions) 
was 50 Gy to PTV1 and 62.5 Gy to PTV2. Two optimal 
treatment plans were then created for each patient using 
Eclipse v13 (Varian): a RA plan (2 arcs, 6MV) and an IMPT plan 
(70 – 250 MeV) using the beam arrangement described by 
Welsh. Dose-volume metrics for PTV1, PTV2, GTV, heart, and 
lung were compared for each patient for the optimal IMPT 
and RA plans (Wilcoxon test). Robustness was evaluated using 
the Plan Uncertainty tool provided in Eclipse. Set-up errors of 
±0.5cm radially and ± 0.7cm axially were simulated to 
generate 6 RA uncertainty plans. An additional range error of 
±3.5% was included for protons, to generate 12 proton 
uncertainty dose distributions. The median values of RA and 
IMPT uncertainty plans were compared using the Mann 
Whitney test.  
Results: Optimal IMPT plans were able to achieve all dose 
constraints for 20/21 patients: the heart mean dose limit of 
25 Gy was exceeded for one patient (25.3 Gy), where there is 
significant overlap with the PTV. IMPT reduced mean lung 
dose for each patient by 49.3% (median, IQR: 46.3 – 52.4%, 
Z=-4.02, p<.001). Mean heart dose was reduced by 40.3% 
(median, IQR: 37.8 – 45.3%, Z=-4.02, p<.001). Analysis of RA 
and IMPT uncertainty plans showed that differences in 
PTV1V95% coverage were not statistically significant for 19/21 
patients. Boost volume coverage (PTV2 V95) was less robust 
for IMPT, and plan uncertainty produced median GTV D98 
across all patients RA= 62.9 Gy (IQR: 62.8 – 63.0 Gy) and 
IMPT= 62.1 Gy (IQR: 61.8 – 62.4 Gy) (p values <.001 to .03). 
Conclusions: IMPT plans have potential for significantly 
sparing lung and heart for all mid-oesophageal patients 
compared to RA. However, the SIB proton plans appear less 
robust for coverage of the dose boost region than photon 
plans, which may compromise the predicted improvement in 
local tumour control for these patients. 
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Purpose/Objective: Currently treatment plan evaluation is 
based on the inspection of the calculated dose distributions 
and dose volume histogram (DVH) parameters. The 
robustness with respect to setup uncertainties of the 
treatment plan is not taken into account in the evaluation 
process. Therefore the risk of missing the target or pushing 
dose to critical organs due to setup uncertainties is 
completely unknown. The purpose of this project is to 
develop a tool to assess the robustness of treatment plans 
taking into account random and systematic setup 
uncertainties. 
Materials and Methods: In order to investigate the effect of 
random and systematic setup errors using Monte Carlo (MC) 
methods, the Swiss Monte Carlo Plan (SMCP) [1] was 
extended accordingly. The impact on the dose distributions is 
evaluated by calculating DVHs and dosimetric parameters as 
a function of the setup error phase-space. The evaluation 
tool allows specifying acceptance criteria by means of dose 
deviations from the original dose distribution. Based on these 
robustness-criteria, a robustness-map is generated dividing 
the setup error phase-space into two regions: one for which 
the robustness-criteria are met (acceptance-space) and 
another treatment-plan where the criteria are not fulfilled. A 
treatment-plan is more robust (in terms of the given 
robustness-criteria), compared to another if the acceptance-
space is larger. In addition, deviations for DVHs or dose 
distributions compared to the original plan can be explored 
across the acceptance-space. 
Results: The robustness evaluation tool is demonstrated on 
various cases and different tumor sites. As an example, 
Figure 1 shows the robustness map comparison of a 2 arcs and 
a 4 arcs plan for a head and neck patient using the VMAT 
delivery technique. In this case, the setup uncertainty phase-
space was defined by translations between [-5mm, 5mm] 
along the x- y- and z-axis. The acceptance-space for the 4 
arcs plan is significantly larger, i.e. more robust with respect 
to setup uncertainties. This is due to the fact that with the 4 
arcs plan, a much better sparing of the spinal cord could be 
achieved. 
Figure1: Robustness-map comparison for a head and neck 
treatment plan applying 2 arcs (left) and 4 arcs (right) using 
the VMAT delivery technique. The acceptance-space 
corresponds to the light grey colored area. The 4 arcs plan is 
superior compared to the 2 arcs plan under the given 
acceptance-criteria. 
 
 
Conclusions: The construction and visualization of 
robustness-maps is useful to assess the robustness of RT 
treatment plans. This work is supported by Varian Medical 
Systems. 
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Purpose/Objective:Cervical cancer patients may benefit 
from intensity-modulated proton therapy (IMPT), preferably 
using a patient-specific beam set-up. However, beam set-up 
optimisation is currently not part of the plan optimisation 
process and the influence of the number of beams on dose 
distributions after robustness evaluation is unknown. The aim 
of this study was to develop a method to determine the 
Pareto front (PF) of robust IMPT plans to enable beam set-up 
selection for robust proton therapy planning in cervical 
cancer. 
Materials and Methods: Planning CTs of 3 cervical cancer 
patients treated in prone position with photons were used. 
Per patient, 3 robustly optimised IMPT base plans using 
different beam set-ups were created with a prescribed dose 
of 46 Gy (23 fractions) to the target (CTV). Beam set-ups, 
planning objectives and minimal requirements for evaluation, 
including the evaluation objectives of interest (CTV D99%, 
rectum V30Gy) which span the objective space, are listed 
(Table). For IMPT plans with a fixed beam set-up, only an 
approximation of the real patient-specific PF can be derived 
and an iterative method to approach this PF was written 
using the scripting facilities in RayStation (RaySearch Labs., 
Sweden). Starting with a base plan, multiple plans with new 
